BoVLP-BVD SIGNED
Tagged (DIVA) polyantigenic vaccine against Bovine Viral Diarrhea virus (BVDv) based on virus-Like-Particles
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BoVLP-BVD project word cloud
Explore the words cloud of the BoVLP-BVD project. It provides you a very rough idea of what is the project "BoVLP-BVD" about.
Project "BoVLP-BVD" data sheet
The following table provides information about the project.
| Coordinator |
AQUILON CYL SOCIEDAD LIMITADA
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 2˙221˙042 € |
| EC max contribution | 1˙554˙729 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-05-01 to 2021-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | AQUILON CYL SOCIEDAD LIMITADA | ES (LEON) | coordinator | 1˙554˙729.00 |
Map
Project objective
In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime. Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals. Aquilón CyL, a leading biotech company, has developed new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. Aquilón has demonstrated the technical, commercial and regulatory feasibility by the SME instrument phase 1 project (nº 774994). After developing the vaccine to TRL6 stage (pre-industrial prototype with positive activity data), Aquilón will develop one vaccine to TRL8 stage, demonstrating the commercial-scale manufacturing and in-vivo safety, efficacy and DIVA attributes in the target species. This vaccine candidate will be licensed to one or more veterinarian pharmaceutical company that will complete the final field studies required for commercialisation. Our business projections, based on agreements with Development milestones and commercial royalties, show potential for a 5X investment multiplier with a 25% internal rate of return.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BOVLP-BVD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BOVLP-BVD" are provided by the European Opendata Portal: CORDIS opendata.